Neil Kumar Sells 31,543 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 31,543 shares of the business’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total value of $1,139,964.02. Following the completion of the transaction, the chief executive officer now directly owns 211,718 shares of the company’s stock, valued at approximately $7,651,488.52. This trade represents a 12.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28.

BridgeBio Pharma Price Performance

BBIO stock traded up $0.80 during trading on Wednesday, reaching $36.29. 4,162,895 shares of the stock traded hands, compared to its average volume of 2,811,407. The business’s 50 day moving average price is $31.53 and its 200-day moving average price is $27.79. The firm has a market capitalization of $6.86 billion, a PE ratio of -15.06 and a beta of 1.07. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $37.81.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently modified their holdings of BBIO. Ironwood Investment Management LLC lifted its position in BridgeBio Pharma by 0.5% during the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company’s stock valued at $1,733,000 after buying an additional 338 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of BridgeBio Pharma by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company’s stock valued at $404,000 after acquiring an additional 466 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after acquiring an additional 472 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after acquiring an additional 801 shares in the last quarter. Finally, Xponance Inc. boosted its position in BridgeBio Pharma by 9.1% during the 4th quarter. Xponance Inc. now owns 10,089 shares of the company’s stock worth $277,000 after purchasing an additional 844 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on BBIO. Scotiabank raised their price target on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 12th. Evercore ISI raised their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Finally, Bank of America increased their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.